

Anti-IL5 (Mepolizumab), Humanized Antibody

07/20

CATALOG NO.: A2158-100 (100 µg)

BACKGROUND DESCRIPTION: The research-grade biosimilar is a humanized IgG1 kappa monoclonal antibody that acts as an antagonist for IL-5. IL-5 is a major cytokine that plays an important role in the recruitment, activation, growth, differentiation, and survival of eosinophil cells. The antibody binds to IL-5 and inhibits its interaction with the IL-5 receptor, localized on the surface of eosinophil cells. This prevents IL-5 mediated signaling and results in reduced survival of eosinophil cells and reduced inflammation. The original drug received approval from the FDA in 2015 for the treatment of severe eosinophilic asthma.

ALTERNATE NAMES: SB 240563, SB-240563, EDF, TRF

ANTIBODY TYPE: Monoclonal

CONCENTRATION: 1 mg/ml

HOST/ISOTYPE: Recombinant / IgG1, kappa

SOURCE: CHO cells

IMMUNOGEN: Human IL-5

CAS NUMBER: 196078-29-2

MOLECULAR WEIGHT: 149 kDa

PURIFICATION: Protein A purified

FORM: Liquid

FORMULATION: In PBS, pH 7.5

SPECIES REACTIVITY: Human

STORAGE CONDITIONS: Store at -80°C

This information is only intended as a guide. The optimal dilutions must be determined by the user

RELATED PRODUCTS:

Anti-IL-4R α (Dupilumab), Human IgG4 Antibody (A2148)

Anti-C5 (Eculizumab), Humanized Antibody (A2138)

Anti-IL-6R α (Sarilumab), Human IgG1 Antibody (A2133)

Anti-IgE (Omalizumab), Humanized Antibody (A2145)

Anti- α 4 β 7 Integrin (Vedolizumab), Humanized Antibody (A2140)

FOR RESEARCH USE ONLY! Not to be used on humans.